Scholarly Productivity Evaluation of KL2 Scholars Using Bibliometrics and Federal Follow-on Funding: Cross-Institution Study.

J Med Internet Res

Clinical and Translational Science Collaborative, School of Medicine, Case Western Reserve University, Cleveland, OH, United States.

Published: September 2021

Background: Evaluating outcomes of the clinical and translational research (CTR) training of a Clinical and Translational Science Award (CTSA) hub (eg, the KL2 program) requires the selection of reliable, accessible, and standardized measures. As measures of scholarly success usually focus on publication output and extramural funding, CTSA hubs have started to use bibliometrics to evaluate the impact of their supported scholarly activities. However, the evaluation of KL2 programs across CTSAs is limited, and the use of bibliometrics and follow-on funding is minimal.

Objective: This study seeks to evaluate scholarly productivity, impact, and collaboration using bibliometrics and federal follow-on funding of KL2 scholars from 3 CTSA hubs and to define and assess CTR training success indicators.

Methods: The sample included KL2 scholars from 3 CTSA institutions (A-C). Bibliometric data for each scholar in the sample were collected from both SciVal and iCite, including scholarly productivity, citation impact, and research collaboration. Three federal follow-on funding measures (at the 5-year, 8-year, and overall time points) were collected internally and confirmed by examining a federal funding database. Both descriptive and inferential statistical analyses were computed using SPSS to assess the bibliometric and federal follow-on funding results.

Results: A total of 143 KL2 scholars were included in the sample with relatively equal groups across the 3 CTSA institutions. The included KL2 scholars produced more publications and citation counts per year on average at the 8-year time point (3.75 publications and 26.44 citation counts) than the 5-year time point (3.4 publications vs 26.16 citation counts). Overall, the KL2 publications from all 3 institutions were cited twice as much as others in their fields based on the relative citation ratio. KL2 scholars published work with researchers from other US institutions over 2 times (5-year time point) or 3.5 times (8-year time point) more than others in their research fields. Within 5 years and 8 years postmatriculation, 44.1% (63/143) and 51.7% (74/143) of KL2 scholars achieved federal funding, respectively. The KL2-scholars of Institution C had a significantly higher citation rate per publication than the other institutions (P<.001). Institution A had a significantly lower rate of nationally field-weighted collaboration than did the other institutions (P<.001). Institution B scholars were more likely to have received federal funding than scholars at Institution A or C (P<.001).

Conclusions: Multi-institutional data showed a high level of scholarly productivity, impact, collaboration, and federal follow-on funding achieved by KL2 scholars. This study provides insights on the use of bibliometric and federal follow-on funding data to evaluate CTR training success across institutions. CTSA KL2 programs and other CTR career training programs can benefit from these findings in terms of understanding metrics of career success and using that knowledge to develop highly targeted strategies to support early-stage career development of CTR investigators.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8515229PMC
http://dx.doi.org/10.2196/29239DOI Listing

Publication Analysis

Top Keywords

kl2 scholars
28
follow-on funding
20
federal follow-on
16
time point
16
scholarly productivity
12
8-year time
12
citation counts
12
kl2
10
evaluation kl2
8
bibliometrics federal
8

Similar Publications

Objective: To describe "What Matters" to older adults seeking emergency department (ED) care and to identify patient characteristics associated with meeting desired outcomes.

Background: As part of the 4Ms framework, identifying "What Matters" has been captured across healthcare settings, yet limited attention has been directed to older adults in the ED.

Methods: We performed a secondary analysis of a multicenter prospective observational study.

View Article and Find Full Text PDF
Article Synopsis
  • - Talimogene laherparapvec (T-VEC) is an innovative treatment made from a modified herpes virus, approved for hard-to-treat melanoma, and this study examines genetic factors that might predict treatment success in patients.
  • - The analysis included data from 93 melanoma patients treated with T-VEC, with 30% showing complete tumor regression; key factors linked to better outcomes included early-stage disease and lack of certain metastases.
  • - Among 54 patients with available genetic data, most had gene mutations, and a specific mutation (TERT promoter) was notably linked to better clinical responses, suggesting it could influence treatment effectiveness.
View Article and Find Full Text PDF
Article Synopsis
  • First-degree relatives of multiple myeloma patients have a higher risk for the disease, yet the role of genetic variants in hereditary cancer genes remains unclear.
  • A study analyzed germline exomes from nearly 1,700 multiple myeloma patients, identifying pathogenic variants in about 8.6-11.5% of cases, particularly in DNA repair genes like BRCA1 and BRCA2.
  • The findings suggest that around 10% of multiple myeloma patients may have an undiagnosed cancer predisposition syndrome, indicating the importance of considering genetic testing for younger patients or those with a family cancer history to inform treatment options.
View Article and Find Full Text PDF

Background: Sleep disturbance in MS is common and can significantly impair overall quality of life. The ketogenic diet (KD) associates with improved sleep quality in people living with epilepsy and may have similar benefits when used within MS; however, the impact of a KD on sleep in this population remains poorly defined.

Methods: Forty-five patients with relapsing MS enrolled into a 6-month KD intervention trial and completed self-reported assessments of sleep quality and sleep disorder symptoms prior to diet initiation and while on diet, using the Epworth Sleepiness Scale (ESS) and Sleep Disorders Symptom Checklist-25 (SDS).

View Article and Find Full Text PDF

Phenibut: A drug with one too many "buts".

Basic Clin Pharmacol Toxicol

October 2024

Center for Dietary Supplements Research, University of Arkansas for Medical Sciences, Little Rock, AR, USA.

Article Synopsis
  • Phenibut is a synthetic drug derived from gamma-aminobutyric acid (GABA), initially created in the Soviet Union to help military personnel with anxiety and cognitive performance.
  • In recent years, it has gained popularity in Europe and the U.S. for its alleged cognitive-enhancing effects (nootropic properties), despite reports of serious adverse health effects, including dependence and withdrawal issues.
  • The lack of understanding regarding its toxicology makes treating phenibut-related health problems difficult, highlighting a need for better drug screening and treatment strategies.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!